Val Bellman

2 papers in the library · 18 citations · publishing 2023-2024

Papers

Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon

Cancers April 27, 2024 Val Bellman 9 citations

Oregon's 2020 legalization of psilocybin therapy for depression in terminal illnesses like advanced cancer has faced significant implementation challenges. This review synthesizes empirical data on psilocybin therapy for cancer-related depression, evaluating benefits and adverse effects. It examines therapeutic strategies, dosing regimens, and barriers to responsible, equitable access, including ethical protocols, healthcare integration, statewide availability, legal ambiguities, and clinical standards. Using Oregon as a case study, the review underscores the need to address regulatory, logistical, and ethical obstacles to establish rigorous and equitable psilocybin care models.

DOI: 10.3390/cancers16091702 Psilocybin Legalization Medicine Psychiatry

Use of ketamine for depression and suicidality in cancer and terminal patients: Review of current data

AIMS Public Health January 1, 2023 Aderonke Oyetunji, C. Blanco Huelga, Kailee Bunte et al. 9 citations

Ketamine may offer rapid relief for depression and suicidality in cancer patients, especially those with advanced disease or near the end of life, where conventional antidepressants often work slowly or poorly. This review of clinical trials and case studies examines ketamine's efficacy and safety as a standalone or combined treatment in this population. The evidence is promising but limited; larger, well-controlled studies with long-term follow-up are needed to confirm effectiveness, safety, and optimal dosing for palliative care.

DOI: 10.3934/publichealth.2023043 Ketamine Anxiety Depression economics Antidepressant +7